Top of this page
Skip navigation, go straight to the content
Company Overview
Corporate Information
| Title | Content |
|---|---|
|
Founded |
1928 |
|
Headquarters |
Brussels, Belgium |
|
Employees |
approx. 10,000 staff |
|
Operations |
over 40 countries |
|
Listing |
Euronext Brussels Stock Exchange |
|
Index |
Bel20 |
|
Ticker |
(UCB / UCB Bt.BR / UCB BB) |
|
ISIN |
BE0003739530 |
|
Free float |
54% |
|
Market cap |
€ 4.9 billion (August 03, 2008) |
Therapeutic areas
Focusing on severe diseases, UCB develops and markets human pharmaceutical products in two core therapeutic areas:
- Central Nervous System (CNS): epilepsy, multiple sclerosis, Parkinson's disease, restless legs syndrome, fibromyalgia, diabetic neuropathic pain
- Immunology disorders: rheumatoid arthritis, Crohn's disease, Lupus
- Other: bone loss disorders, non-small-cell lung cancer, non-Hodgkin's lymphoma, overactive bladder
- Also has a selective presence in primary care
Learn more about UCB's leading therapeutic areas.
Net Sales by therapeutic area
Net Sales 2007 by therapeutic areas €3188 million
.gif)
Net Sales by geography
Net Sales 2007 by geography €3188 million
.gif)
Net Sales - Top Selling Products:
